| Literature DB >> 19039677 |
Hervé Javelot1, Alexandre Baratta, Luisa Weiner, Thierry Javelot, Cathy Nonnenmacher, Jean-Frédéric Westphal, Michaël Messaoudi.
Abstract
Bupropion is an antidepressant drug also used as a smoking cessation aid, which inhibits norepinephrine and dopamine re-uptake. Given its pharmacological properties, it has been associated with reports on psychosis and acute delirious episodes. Case We report the case of a patient with schizoaffective disorder who developed two psychotic episodes respectively after a four and a two-day administration of sustained-release (SR) bupropion at a dose of 150 mg/day. To our knowledge, this is the first reported case of involuntary rechallenge with bupropion SR during a smoking cessation program. Conclusion There is a serious risk of incorrectly identifying bupropion as only a therapy for nicotine withdrawal without taking the precaution of exploring possible psychiatric co-morbidity with addiction. Our case illustrates the problem.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19039677 DOI: 10.1007/s11096-008-9272-x
Source DB: PubMed Journal: Pharm World Sci ISSN: 0928-1231